Yuki Kawata
Research Subjects
Yuki Kawata has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ayuko Kimura
Department of Health Science, Gunma Paz University Graduate School, Takasaki 370-0006, Gunma, Japan
1 shared publication - Hirokazu Kimura
Department of Clinical Engineering, Faculty of Medical Science and Technology, Gunma Paz University, Takasaki 370-0006, Japan
1 shared publication - Hisashi Hirano
Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
1 shared publication - Kiyotaka Fujita
Department of Health Science, Gunma Paz University Graduate School of Health Sciences, Takasaki-shi 370-0006, Gunma, Japan
1 shared publication - Natsumi Sato
Department of Health Sciences, Gunma Paz University Graduate School of Health Sciences, 1-7-1, Tonyamachi, Takasaki-shi, Gunma 370-0006, Japan
1 shared publication - Ren Takahashi
Department of Health Sciences, Gunma Paz University Graduate School of Health Sciences, 1-7-1, Tonyamachi, Takasaki-shi, Gunma 370-0006, Japan
1 shared publication
Latest Publications
- Open Access
- 10 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 1766
Detailed Structure and Pathophysiological Roles of the IgA-Albumin Complex in Multiple Myeloma
Immunoglobulin A (IgA)-albumin complexes may be associated with pathophysiology of multiple myeloma, although the etiology is not clear. Detailed structural analyses of these protein–protein complexes may contribute to our understanding of the pathophysiology of this disease. We analyzed the structure of the IgA-albumin complex using various electrophoresis, mass spectrometry, and in silico techniques. The data based on the electrophoresis and mass spectrometry showed that IgA in the sera of patients was dimeric, linked via the J chain. Only dimeric IgA can bind to albumin molecules leading to IgA-albumin complexes, although both monomeric and dimeric forms of IgA were present in the sera. Molecular interaction analyses in silico implied that dimeric IgA and albumin interacted not only via disulfide bond formation, but also via noncovalent bonds. Disulfide bonds were predicted between Cys34 of albumin and Cys311 of IgA, resulting in an oxidized form of albumin. Furthermore, complex formation prolongs the half-life of IgA molecules in the IgA-albumin complex, leading to excessive glycation of IgA molecules and affects the accumulation of IgA in serum. These findings may demonstrate why complications such as hyperviscosity syndrome occur more often in patients with IgA dimer producing multiple myeloma.
- 10 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 1766
Open AccessDetailed Structure and Pathophysiological Roles of the IgA-Albumin Complex in Multiple Myeloma
Immunoglobulin A (IgA)-albumin complexes may be associated with pathophysiology of multiple myeloma, although the etiology is not clear. Detailed structural analyses of these protein–protein complexes may contribute to our understanding of the pathophysiology of this disease. We analyzed the structure of the IgA-albumin complex using various electrophoresis, mass spectrometry, and in silico techniques. The data based on the electrophoresis and mass spectrometry showed that IgA in the sera of patients was dimeric, linked via the J chain. Only dimeric IgA can bind to albumin molecules leading to IgA-albumin complexes, although both monomeric and dimeric forms of IgA were present in the sera. Molecular interaction analyses in silico implied that dimeric IgA and albumin interacted not only via disulfide bond formation, but also via noncovalent bonds. Disulfide bonds were predicted between Cys34 of albumin and Cys311 of IgA, resulting in an oxidized form of albumin. Furthermore, complex formation prolongs the half-life of IgA molecules in the IgA-albumin complex, leading to excessive glycation of IgA molecules and affects the accumulation of IgA in serum. These findings may demonstrate why complications such as hyperviscosity syndrome occur more often in patients with IgA dimer producing multiple myeloma.